Back

The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Stroke prevention in atrial fibrillation Oral Anticoagulation ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Tim Anthonie Christiaan de Vries

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Associations of soluble fms-like tyrosine kinase-1 with cardiovascular events and stroke in patients with atrial fibrillation and suspected or known coronary artery disease: The EXCEED-J Study
Doctor K. Hasegawa (Kyoto, JP)
Abstract Slides
Presentation thumbnail
Prediction of atrial fibrillation in patients with embolic stroke with undetermined source using electrocardiogram deep learning algorithm and clinical risk factors
Associate Professor J. Lee (Seongnam, KR)
Abstract Slides
Presentation thumbnail
We all know A and B, but what about C? Exploring the management of modifiable risk factors in patients with atrial fibrillation.
Miss D. Verhaert (Maastricht, NL)
Abstract Slides
Presentation thumbnail
Incidence and risk factors for major bleeding events in atrial fibrillation patients on direct oral anticoagulant therapy: data from the National Patient-Centered Clinical Research Network
Doctor K. Arps (Durham, US)
Abstract Slides
Presentation thumbnail
Should we initiate oral anticoagulants for patients with atrial fibrillation staying well without oral anticoagulants for years?
Doctor T. Chao (Taipei, TW)
Abstract Slides

Access the full session

Session thumbnail
Stroke prevention in atrial fibrillation

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources